Conditioning intensity in middle-aged patients with AML in first CR: No advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT

Bone Marrow Transplantation

Volumn 50, Issue 8, 2015, Pages 1063-1068

  Passweg, J R ^a   Labopin, M ^b   Cornelissen, J ^c   Volin, L ^d   Socie G ^e   Huynh, A ^f   Tabrizi, R ^g   Wu, D ^h   Craddock, C ⁱ   Schaap, N ^j   Kuball, J ^k   Chevallier, P ^l   Cahn, J Y ^m   Blaise, D ⁿ   Ghavamzadeh, A ^o   Bilger, K ^p   Ciceri, F ^q   Schmid, C ^r   Giebel, S ^s   Nagler, A ^t   Mohty, M ^u   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b The European EBMT Data Office in Paris   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e SAINT LOUIS HOSPITAL   (France)

^f CHU PURPAN   (France)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h SOOCHOW UNIVERSITY   (China)

ⁱ QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^l NANTES UNIVERSITY HOSPITAL   (France)

^m GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁿ INSTITUT PAOLI CALMETTES   (France)

^o TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^p HÔPITAL DE HAUTEPIERRE   (France)

^q SAN RAFFAELE HOSPITAL   (Italy)

^r KLINIKUM AUGSBURG   (Germany)

^s INSTITUTE OF ONCOLOGY   (Poland)

^t SHEBA MEDICAL CENTER   (Israel)

^u HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GRAFT REJECTION; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; ALLOGRAFT; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROCEDURES; RISK FACTOR; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

ADULT; ALLOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 84938955303     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.121     Document Type: Article

References (27)

1. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487-494
2. Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012; 9: 579-590
3. Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 2013; 88: 318-327
4. Magenau J, Couriel DR. Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how. Curr Oncol Rep 2013; 15: 436-444
5. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet 2013; 381: 484-495
6. Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood 2013; 121: 1077-1082
7. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918
8. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633
9. Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood 2014; 124: 344-353
10. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-2312
11. Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol 2013; 31: 701-709
12. Ringdén O, Erkers T, Aschan J, Garming-Legert K, Le Blanc K, Hägglund H, et al. A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. J Intern Med 2013; 274: 153-162
13. Shimoni A, Hardan I, Shem-Tov N, Yerushalmi R, Nagler A. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up. Leukemia 2010; 24: 1050-1052
14. Todisco E, Ciceri F, Oldani E, Boschini C, Micò C, Vanlint MT, et al. The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. Leukemia 2013; 27: 2086-2091
15. Luger SM, Ringdén O, Zhang MJ, Pérez WS, Bishop MR, Bornhauser M, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47: 203-211
16. Martino R, de Wreede L, Fiocco M, van Biezen A, von dem Borne PA, Hamladji RM, et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with o10% BM blasts: a report from EBMT. Bone Marrow Transplant 2013; 48: 761-770
17. Versluis J, Labopin M, Niederwieser D, Socie G, Schlenk RF, Milpied N, et al. Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Leukemia 2014; 29: 51-57
18. Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, et al. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood 2014; 123: 1615-1620
19. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836-846
20. Lioure B, Béné MC, Pigneux A, Huynh A, Chevallier P, Fegueux N, et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. Blood 2012; 119: 2943-2948
21. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457-481
23. Gooley TA, Leisenring W, Crowley JA, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706
24. Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol 2013; 66: 648-653
25. Grambsch PMTT. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515-526
26. Grossmann V, Schnittger S, Kohlmann A, Eder C, Roller A, Dicker F, et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012; 120: 2963-2972
27. Röllig C, Bornhäuser M, Kramer M, Thiede C, Ho AD, Krämer A, et al. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. J Clin Oncol 2015; 33: 403-410